Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 4/20 | 0.43 |
| ▸ | F13A1 | P00488 | 3/20 | 0.43 |
| ▸ | TGM1 | P22735 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640469 | 0.83 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL3605204 | 0.78 | MAPT (0.71) | SMN1; SMN2PTPN2PTPN1PTPN6MAPT | |
| SCHEMBL2294464 | 0.77 | TRPV1 (0.44) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL28455754 | 0.75 | PTPN1 (0.81) | RAB9ANPC1PTPN2PTPN1PTPN6 | |
| SCHEMBL2292999 | 0.74 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL2291227 | 0.74 | HPGDS (0.53) | SMN1; SMN2ALDH1A1ABL1LMNA | |
| SCHEMBL2294293 | 0.74 | GRIN2B (0.50) | RAB9ASMN1; SMN2MAPTALDH1A1GAA | |
| SCHEMBL22315264 | 0.73 | ALDH1A1 (0.62) | MAPTALDH1A1GAALMNA | |
| SCHEMBL632848 | 0.72 | MEN1 (0.54) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL2294335 | 0.72 | RAB9A (0.58) | RAB9ASMN1; SMN2MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | RAB9A 2436/4885SMN1; SMN2 993/4885NPC1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.